Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study

Figures & data

Figure 1 Study flow.

Abbreviations: EGFR, epithelial growth factor receptor; GPP, gefitinib plus pemetrexed/platinum.

Table 1 Clinical Characteristics of Patients with EGFR-Mutated Advanced Lung Adenocarcinoma

Items	GPP Group (N = 51)	Control Group (N = 30)	P value
Age (years), mean±SD	56.6±10.0	58.3±8.0	0.449
Gender, No. (%)			0.138
Male	29 (56.9)	22 (73.3)
Female	22 (43.1)	8 (26.7)
History of smoking, No. (%)	21 (41.2)	17 (56.7)	0.177
Family history of cancer, No. (%)	7 (13.7)	5 (16.7)	0.971
ECOG PS score, No. (%)			0.739
0	5 (9.8)	2 (6.7)
1	41 (80.4)	25 (83.3)
2	5 (9.8)	3 (10.0)
T stage, No. (%)			0.499
T1	3 (10.0)	4 (7.8)
T2	10 (33.3)	11 (21.6)
T3	5 (16.7)	15 (29.4)
T4	12 (40.0)	21 (41.2)
N stage, No. (%)			0.955
N0	6 (20.0)	8 (15.7)
N1	4 (13.3)	8 (15.7)
N2	11 (36.7)	21 (41.2)
N3	9 (30.0)	14 (27.5)
M stage, No. (%)			0.485
M0	4 (13.3)	5 (9.8)
M1	6 (20.0)	14 (27.5)
M2	9 (30.0)	6 (11.8)
M3	11 (36.7)	26 (51.0)
Site of tumor metastasis, No. (%)
Bone	20 (39.2)	10 (33.3)	0.597
Brain	9 (17.6)	7 (23.3)	0.535
Liver	7 (13.7)	3 (10.0)	0.887
Others	37 (72.5)	18 (60.0)	0.243
Site of EGFR mutation, No. (%)			0.742
Exon 19 deletion	28 (54.9)	14 (46.7)
L858R	21 (41.2)	15 (50.0)
Others	2 (3.9)	1 (3.3)

Abbreviations: EGFR, epithelial growth factor receptor; GPP, gefitinib plus pemetrexed/platinum; SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; PS, performance status.

Figure 2 Cumulative PFS and OS. Comparison of cumulative PFS rate (A) and OS rate (B) between GPP group and control group.

Abbreviations: PFS, progression-free survival; OS, overall survival; CI, confidence interval; EGFR, epithelial growth factor receptor; GPP, gefitinib plus pemetrexed/platinum.

Figure 3 Related factors for PFS. Univariate and multiple Cox proportional hazard regression were conducted to explore risk factors for PFS with P value and crude HR (95% CI).

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; EGFR, epithelial growth factor receptor; TNM, tumor node metastasis; HR, hazard ratio; CI, confidence interval; PFS, progression-free survival; GPP, gefitinib plus pemetrexed/platinum.

Figure 4 Related factors for OS. Univariate and multiple Cox proportional hazard regression were conducted to explore risk factors for OS with P value and crude HR (95% CI).

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; EGFR, epithelial growth factor receptor; TNM, tumor node metastasis; HR, hazard ratio; CI, confidence interval; OS, overall survival; GPP, gefitinib plus pemetrexed/platinum.

Table 2 Adverse Events in GPP Group

Adverse Events	Total	Grade 1	Grade 2	Grade 3	Grade 4
Myelosuppression, No. (%)	34 (66.7)	7 (13.7)	14 (27.5)	9 (17.6)	4 (7.8)
Digestive toxicity, No. (%)	32 (62.7)	8 (15.7)	13 (25.5)	11 (21.6)	0 (0.0)
Renal toxicity, No. (%)	16 (31.4)	15 (29.4)	1 (2.0)	0 (0.0)	0 (0.0)
Hepatotoxicity, No. (%)	12 (23.5)	8 (15.7)	4 (7.8)	0 (0.0)	0 (0.0)
Neurotoxicity, No. (%)	3 (5.9)	3 (5.9)	0 (0.0)	0 (0.0)	0 (0.0)
Baldness, No. (%)	2 (4.0)	1 (2.0)	1 (2.0)	0 (0.0)	0 (0.0)
Cardiotoxicity, No. (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)